ImmunityBio, Inc. IBRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $44.21M+15.5% | $38.29M+19.4% | $32.06M+21.3% | $26.43M+60.0% | $16.52M+119% | ||
| $238K-37.7% | $382K+116% | $177K+30.1% | $136K+134% | $58K— | ||
| $43.97M+16.0% | $37.9M+18.9% | $31.88M+21.3% | $26.29M+59.7% | $16.46M+118% | ||
| 99.5%+0.5pp | 99%-0.4pp | 99.4%0.0pp | 99.5%-0.2pp | 99.6%-0.4pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $114M+10.7% | $102.97M+17.4% | $87.69M-10.3% | $97.71M+20.7% | $80.95M+5.2% | ||
| -$69.79M-7.9% | -$64.68M-16.3% | -$55.63M+22.0% | -$71.29M-10.6% | -$64.43M+7.2% | ||
| -157.9%+11.1pp | -169%+4.6pp | -173.5%+96.3pp | -269.8%+120pp | -390.1%+529pp | ||
| $13.87M+12.8% | $12.3M0.0% | $12.3M-8.2% | $13.41M-1.0% | $13.53M+17.7% | ||
| -$563M— | $0+100% | -$11.68M+44.4% | -$21.02M+67.9% | -$65.47M— | ||
| $2.31M+0.7% | $2.3M+11.2% | $2.07M+79.3% | $1.15M+30.0% | $887K-25.3% | ||
| -$632.79M-919% | -$62.09M+7.7% | -$67.31M+27.1% | -$92.31M+28.9% | -$129.9M-120% | ||
| $9K+107% | -$135K-286% | -$35K-113% | $269K+215% | -$234K— | ||
| -$632.78M-922% | -$61.94M+7.9% | -$67.25M+27.3% | -$92.56M+28.6% | -$129.65M-119% | ||
| -1,431.4%-1,270pp | -161.8%+48.0pp | -209.8%+140pp | -350.3%+435pp | -784.9%-1.5pp | ||
| -$0.62-933% | -$0.06+14.3% | -$0.07+30.0% | -$0.10+33.3% | -$0.15-66.7% | ||
| -$0.62-933% | -$0.06+14.3% | -$0.07+30.0% | -$0.10+33.3% | -$0.15-114% | ||
| 1B+11.6% | 919.9M-2.8% | 946.6M+6.6% | 888.2M+4.1% | 853.2M+21.8% | ||
| 1B+11.6% | 919.9M-2.8% | 946.6M+6.6% | 888.2M+4.1% | 853.2M+22.4% | ||
| $1.11M— | —— | $289K-85.0% | $1.93M-65.4% | $5.58M— | ||
| -$236.63M-123,787% | -$191K+83.7% | -$1.17M— | $0+100% | -$42.58M-198% | ||
| -$5.92M-255% | -$1.67M-792% | -$187K+32.7% | -$278K-578% | -$41K— | ||
| $44.21M+15.5% | $38.29M+19.4% | $32.06M+21.3% | $26.43M+60.0% | $16.52M+119% | ||
| -$69.79M-7.9% | -$64.68M-16.3% | -$55.63M+22.0% | -$71.29M-10.6% | -$64.43M+7.2% | ||
| -$65.41M-7.6% | -$60.82M-17.7% | -$51.68M+23.3% | -$67.41M-11.2% | -$60.6M+7.1% | ||
| -$65.41M-7.6% | -$60.82M-17.7% | -$51.68M+23.3% | -$67.41M-11.2% | -$60.6M+7.1% | ||
| -148%+10.9pp | -158.9%+2.3pp | -161.2%+93.9pp | -255.1%+112pp | -366.9%+497pp | ||
| -$69.79M-7.9% | -$64.68M-16.3% | -$55.63M+22.0% | -$71.29M-10.6% | -$64.43M+7.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. (IBRX) generated $141.0M in revenue over the trailing twelve months, up 351.5% year over year.
- Is ImmunityBio, Inc. profitable?
- ImmunityBio, Inc. is not currently profitable: it reported a net loss of $854.5M over the trailing twelve months, a -606.2% net margin.
- What are ImmunityBio, Inc.'s profit margins?
- Gross margin is 99.3% and operating margin is -185.4%, with a -606.2% net margin.
- What is ImmunityBio, Inc.'s earnings per share?
- ImmunityBio, Inc.'s diluted EPS over the trailing twelve months is $-0.85.
- Where does ImmunityBio, Inc.'s income statement data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
